Literature DB >> 3009609

Release of lymphokines after infection with Epstein Barr virus in vitro. II. A monocyte-dependent inhibitor of interleukin 1 downregulates the production of interleukin 2 and interferon-gamma in rheumatoid arthritis.

M Lotz, C D Tsoukas, S Fong, C A Dinarello, D A Carson, J H Vaughan.   

Abstract

Epstein Barr virus (EBV)-infection of normal peripheral blood mononuclear cells (PBMC) in vitro induces IFN-alpha secretion from B cell and natural killer (NK) cell populations, and IFN-gamma secretion from T cells. IFN-gamma depends on prior elaboration of IL 2 and IL 1 that originates from monocytes and NK cells. PBMC from rheumatoid arthritis (RA) patients released moderately elevated levels of IFN-alpha (236 +/- 62 U/ml vs 168 +/- 34 in normals). In contrast, IFN-gamma was significantly lower in RA (88 +/- 34 U/ml vs 209 +/- 32) with an associated deficit in IL 2. A monocyte-dependent factor was shown to be responsible for this deficit, since monocyte depletion of RA cultures normalized the levels of IL 2 and IFN-gamma. Significantly lower levels of IL 1 activity were present in the supernatants of RA PBMC cultures as compared with normal cultures, and this was shown to be associated with presence of a nondialyzable IL 1 inhibitor. This inhibitor was capable of preventing the IL 1-dependent synthesis of IL 2 and IFN-gamma by normal PBMC. Exogenous IL 1 or IL 2 restored the deficient IFN-gamma secretion in RA PBMC. Thus, the deficient ability of RA lymphocytes to control EBV infection may be secondary to impairment of a monocyte-T cell interaction at the level of IL 1.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009609

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Possible involvement of IL-12 expression by Epstein-Barr virus in Sjögren syndrome.

Authors:  M Horiuchi; S Yamano; H Inoue; J Ishii; Y Nagata; H Adachi; M Ono; J N Renard; F Mizuno; Y Hayashi; I Saito
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

2.  Basis for defective responses of rheumatoid arthritis synovial fluid lymphocytes to anti-CD3 (T3) antibodies.

Authors:  M Lotz; C D Tsoukas; C A Robinson; C A Dinarello; D A Carson; J H Vaughan
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

3.  Cytokine production in a whole-blood assay after Epstein-Barr virus infection in vivo.

Authors:  M W Hornef; H J Wagner; A Kruse; H Kirchner
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

4.  Differential immunological response of patients with rheumatoid arthritis towards two different Epstein-Barr virus strains: inhibition of interleukin-1 release by the B95-8, but not the P3HR-1 virus strain.

Authors:  T Häupl; G R Burmester; G Hahn; U Feige; C Rordorf-Adam; J R Kalden
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

5.  Impaired autologous mixed lymphocyte reaction (AMLR) reactivity of peripheral blood T cell subsets in rheumatoid arthritis.

Authors:  E C Keystone; L Poplonski; K M Snow; M Martell
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

6.  Increased polyamines may downregulate interleukin 2 production in rheumatoid arthritis.

Authors:  E Flescher; T L Bowlin; A Ballester; R Houk; N Talal
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

Review 7.  The Epstein-Barr virus in autoimmunity.

Authors:  J H Vaughan
Journal:  Springer Semin Immunopathol       Date:  1995

8.  Spontaneous and in vitro activation of synovial fluid and peripheral blood lymphocytes in rheumatoid arthritis.

Authors:  Y T Konttinen; T Pettersson; P Kemppinen; C Friman
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

9.  Release of interleukin 1 inhibitory activity (contra-IL-1) by human monocyte-derived macrophages infected with human immunodeficiency virus in vitro and in vivo.

Authors:  R M Locksley; S Crowe; M D Sadick; F P Heinzel; K D Gardner; M S McGrath; J Mills
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

10.  Production of an interleukin-1 inhibitor by cell line P388D1 murine macrophages stimulated with Haemophilus actinomycetemcomitans lipopolysaccharide.

Authors:  T Nishihara; T Koga; S Hamada
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.